Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Tear trough filler, using HA, offers a nonsurgical option for under-eye rejuvenation, requiring precise anatomical knowledge ...

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved ...

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular ...

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the ...

New presbyopia-correcting eye drops, including VIZZ and Qlosi, offer alternatives to Vuity, with more options under FDA ...

Danny A. Mammo, MD, a vitreoretinal surgeon and uveitis specialist at the Cole Eye Institute at Cleveland Clinic, presented research on the association between androgen exposure and central serous ...

The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of ...